Provectus Biopharmaceuticals Expands Global Patent Portfolio for Cancer Combination Therapy

Wednesday April 18, 2018

 

KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that the Japan Patent Office (JPO) had granted and the European Patent Office (EPO) had allowed the Company's patent application for the combination of PV-10 with systemic immunomodulatory therapy (i.e., immune checkpoint inhibition). Pfizer, Inc. is a co-assignee on the award and allowance.

The JPO patent and EPO patent allowance are related to U.S. patent (USP) 9,839,688, "Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer," which was awarded by the United States Patent and Trademark Office (USPTO) in December 2017. USP 9,839,688 is one of the continuations of the Company's foundational cancer combination therapy patent, USP 9,107,887, which was awarded by the USPTO in August 2015.

Provectus' patent portfolio provides global intellectual property protection into the 2030s for the synthesis and use of PV-10 and other halogenated xanthene-based therapeutics as monotherapies and part of combination therapies for cancer.

About PV-10

Provectus’ lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. It elicits tumor immunity via activation of dendritic cells mediated by the release of damage-associated molecular pattern molecules. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.

About Provectus

Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).

Contact:

Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.
President
Phone: 866-594-5999

NEWSLETTER
Errors